F8 and hemophilia: Using hemophilia A mice on a BALB/c background, data from this study demonstrate that AAV8-hAAT-hfVIII (1011 vg/mouse) gene therapy can not only correct fVIII levels, but also results in low to no detectable inhibitor titers following subsequent challenge with recombinant human fVIII.